CannabisNewsBreaks

ThursdayJun 02, 2022 11:39 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces $5M Registered Direct and Private Placement Offerings

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced its entry into securities purchase agreements with a single health care-focused institutional investor for the issuance and sale of 4,079,256 of its common shares, each at a purchase price of $0.858 (or pre-funded warrant in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, InMed has also agreed to issue and sell to the investor 1,748,250 common shares (or pre-funded warrant in lieu thereto) at the same purchase price as in…

Continue Reading

WednesdayJun 01, 2022 1:42 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on 2022 Annual Meeting Voting

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released a report on its recent 2022 Annual Meeting and the items that were voted on. The meeting was held on May 31, 2022, at 1 p.m. PT. According to the announcement, 2,927,321 shares of the company were represented in person or by proxy during the meeting; that number comprised 49.2% of Lexaria’s issued share capital as of April 4, 2022, which is the record date of the meeting. All matters voted on during the meeting were passed by a majority. Those matters included electing Chris Bunka, John Docherty,…

Continue Reading

TuesdayMay 31, 2022 12:44 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Launch of JustCBD Products on Amazon.co.uk

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that its wholly-owned subsidiary JustCBD will be launching its line of Novel Foods-registered CBD products on Amazon.co.uk. Since its entry into the now £700 million CBD market in October 2021, Amazon U.K. has expanded the initial pilot-only program to include vendors who have demonstrated compliance with U.K. CBD Novel Food regulations. Producers awarded U.K. Novel Food authorization must prove the product is safe for consumption and labeled correctly. “With health and wellness playing an increasingly important role in customers’ lives, we are…

Continue Reading

FridayMay 27, 2022 2:57 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) as It Looks to Tap into Various Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX) has been pushing the boundaries of drug delivery through its patented DehydraTECH(TM) technology, which has evidenced more efficient delivery of active pharmaceutical ingredients (“APIs”) into the bloodstream while also increasing their bioavailability. “Its technology has seen application in pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, and oral suspensions. Lexaria has explored its usage in the delivery of cannabinoids, nicotine, antivirals, PDE5 inhibitors, and more,” a recent article reads. “All of Lexaria’s efforts serve to demonstrate the superior performance of both its research program and its DehydraTECH drug delivery technology. By doing so,…

Continue Reading

MondayMay 23, 2022 11:05 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Acquisition of Masaya CB Brand

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, has signed an agreement to acquire Masaya and its patent-pending CBD formulations, including Masaya Pure. The agreement was made with leading cell biologist Dr. Annabelle Manalo-Morgan, PhD, who created and owns the brand; Manalo-Morgan is a member of Flora Growth’s board of directors and is the company’s scientific advisor. According to the announcement, Masaya’s exclusive CBD oil formulations contain no THC and have garnered numerous testimonials. The brand will be the first offering from Flora Life Sciences in the United States, and the…

Continue Reading

ThursdayMay 19, 2022 2:38 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Aims to Deliver Safer Alternative for Nicotine Experience

Lexaria Bioscience Corp. (NASDAQ: LEXX) will soon begin a human clinical study, NIC-H22-1, to compare its DehydraTECH-nicotine pouch performance with that of existing brands such as ON! and Zyn, currently available in the U.S. “Animal testing has already demonstrated that DehydraTECH-nicotine can deliver peak nicotine performance to the bloodstream 10 to 20 times faster than the study’s controls,” a recent article reads. “Lexaria has long held that any form of inhaling chemical substances can be detrimental to health, and its DehydraTECH-nicotine aims to help vapers as well as smokers wean themselves off of those products, giving them relief from cravings…

Continue Reading

WednesdayMay 18, 2022 11:34 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Upcoming Cannabis Landscape Webinar, Launches Highsman Helix

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, is hosting a webinar focused on the global cannabis regulatory landscape; the event is scheduled for Thursday, May 19, at 4 p.m. EDT. Titled “The State of the Play: Cannabis Regulatory Landscape,” the webinar will feature Flora Growth executives, including president and CEO Luis Merchan, COO Jason Warnock and newly appointed VP of regulatory affairs Holly Bell. The webinar agenda includes an overview of the opportunities and challenges facing Flora and other cannabis companies operating in the United States, Colombia and other global…

Continue Reading

WednesdayMay 18, 2022 11:21 am

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Releases Status Update Regarding MCTO

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, has shared a status update on the management cease trade order (“MCTO”) the company received from the British Columbia Securities Commission; the MCTO was effective on May 3, 2022, under the National Policy 12-203. In the update, the company references its original press release, which announced a delay in the filing of key financial statements and accompanying management’s discussion and analysis for FY 2021, a delay that would extend beyond the period outlined in the applicable Canadian securities laws. The update also noted…

Continue Reading

MondayMay 16, 2022 1:33 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Strategic Appointment of Cannabis Regulatory Veteran

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced its appointment of regulatory veteran Holly Bell as vice president of regulatory affairs. According to the update, Bell will play a crucial role in Flora’s domestic and global expansion strategy and lead government relations in key international markets. “Holly’s unique knowledge and understanding of the United States’ regulatory framework will position us to make thoughtful, educated and bold decisions regarding strategic distribution, cultivation and sales plans,” said Luis Merchan, president and CEO of Flora Growth. “We look forward to bringing Holly’s expertise…

Continue Reading

FridayMay 13, 2022 1:54 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Devoting Research, Product Development to Make Drug Substances More Effective

Lexaria Bioscience Corp. (NASDAQ: LEXX) is devoting its research and product development to making drug substances more effective in the approach to treating medical conditions such as high blood pressure and, in the process, to overcoming many obstacles that may hinder their proper use by patients. “One area of Lexaria’s research has focused on pursuing U.S. Food and Drug Administration (‘FDA’) approval to begin formal, registered clinical testing of its DehydraTECH-processed cannabidiol (‘CBD’) for the treatment of hypertension under the Investigational New Drug (‘IND’) process,” a recent article reads. “Lexaria recently announced the launch of its HYPER-H21-4 randomized, double-blinded, placebo-controlled,…

Continue Reading